GlassScriptPhysician profile
Nicholas Lemley
NPI 1457885592
$1,393.90
in general payments reported to CMS, 2019-2025
34 companies · $52.11 in 2025
The $52.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $176 · 2021: $395 · 2022: $327 · 2023: $309 · 2024: $135 · 2025: $52.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $161.70 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $129.21 | 2021-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.27 | 2021-2024 | Ofev, Jardiance |
| Otsuka America Pharmaceutical, INC. | $89.70 | 2020-2023 | Rexulti |
| Novo Nordisk INC | $64.11 | 2021-2022 | |
| Intuitive Surgical, INC. | $62.86 | 2023 | Da Vinci Surgical System |
| Abbvie INC. | $58.99 | 2021-2023 | |
| Glaxosmithkline, LLC. | $57.32 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $56.32 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Sun Pharmaceutical Industries INC. | $54.05 | 2020-2021 | |
| Lilly USA, LLC | $44.21 | 2021-2022 | |
| Amgen INC. | $36.97 | 2020-2021 | |
| Smith+Nephew, INC. | $35.71 | 2022 | |
| Shield Therapeutics INC | $35.34 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $32.00 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $31.64 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.36 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.30 | 2022 | |
| Tactile Systems Technology INC | $25.63 | 2023 | Entre Plus, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $25.52 | 2022 | |
| Solventum Corporation | $25.23 | 2024 | Prevena |
| Amarin Pharma, INC. | $22.89 | 2020 | |
| Xeris Pharmaceuticals, INC. | $20.75 | 2022 | |
| Kci USA, INC. | $19.16 | 2023 | Prevena |
| Biohaven Pharmaceutical Holding Company LTD. | $18.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.62 | 2022 | |
| Averitas Pharma INC. | $18.17 | 2023 | Qutenza |
| Sanofi Pasteur INC. | $15.77 | 2021 | |
| Ardelyx, INC. | $14.92 | 2024 | Ibsrela |
| Astellas Pharma US INC | $14.39 | 2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.15 | 2024 | Xifaxan, Trulance |
| Genentech USA, INC. | $11.96 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.11 | 2020 | |
| Organon LLC | $7.73 | 2025 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lemley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.